Is it possible to desensitize to peanut allergy
This content has not been reviewed within the past year and may not represent WebMD's most up-to-date information. See the latest news and features on Allergies. Small doses of possilbe protein, given for months under medical supervision, can desensitize children with peanut allergyreducing the risk of a reaction if they accidentally eat peanuts, according to a new study. In other new research, scientists say they have found a way to predict which children are likely to outgrow their allergy to peanuts. Reactions can range from mild to severe, even leading pkssible anaphylaxisa potentially fatal response that can cause breathing problems and loss of consciousness.
Published Online: September 5, Oral immunotherapy is a promising approach to treating food allergies, allowing patients to build up tolerance by consuming the food in initially small and gradually increasing amounts. However, many patients have hypersensitivity reactions during the desensitization process, forcing them to discontinue therapy.
One appealing new approach to decreasing reactions in highly allergic patients is to add omalizumab, an anti-IgE antibody approved for use in severe asthma and chronic urticaria. In the current issue of The Journal of Allergy and Clinical Immunology JACILynda Schneider and colleagues examine the efficacy of omalizumab in facilitating peanut desensitization in 37 highly allergic patients.
The double-blind, placebo-controlled study took place at four U. Allen and her colleagues followed children with peanut allergies, some for years, to see if the size of the wheal over time could predict allergy. The children entered the study at an average age of 14 months -- the time when most infants first show peanut sensitivity, Allen says.
Once allergg size of the wheal peanut came after a prick fell sufficiently, the scientists would give a food challenge to see if the child had outgrown desensitize allergy. The severity of the initial reaction, however, did not predict tolerance.
The results offer valuable information not just for parents whose children do outgrow it, possible says, but also for those whose children are not likely to and therefore may need closer follow-up. Related to Allergies Allergies or Cold?Peanut-allergic patients achieve rapid desensitization with omalizumab. This study indicates that omalizumab allows rapid desensitization to peanut during oral immunotherapy and may be an attractive therapy for patients with severe peanut allergy. The Journal of Allergy and Clinical Immunology (JACI) is an official scientific journal of the AAAAI. Jul 16, · yes and thbp.alexeevphoto.ru depends if it has any main allergies to rose thbp.alexeevphoto.ru is possible to gain any allergies no matter what you are. Nov 21, · The treatment is not a cure for peanut allergy. Nor is it designed to allow kids to eat entire peanut butter and jelly thbp.alexeevphoto.ru: Shawn Radcliffe.
Allergies News. About Immunotherapy For years, allergists have used immunotherapy, or allergy shots, to help children with allergies to insect stings and nasal allergies to non-food substances, for example.
With immunotherapy, tiny amounts of the allergens are injected until tolerance develops.Is desensitization possible for dog allergies - Answers
Oral Peanut Immunotherapy So Nash's team decided to try oral immunotherapy for peanut allergy problems, giving eight children with known peanut allergy escalating doses desenstize peanut protein in the form of a flour mixed into applesauce or other food. Continued Goals of Immunotherapy "What we would like to have happen is for their food allergy to go away," Allergt says.
More research is needed, he says, to prove the concept safe and effective.
Until recently, doctors could only posxible. It's the extreme of the widespread, still unexplained rise in allergies. Then, 10 to 12 years ago, the second wave began. Now kids have to bring their EpiPens to school. Desensitization has been widely studied for the past few years as a treatment for food allergies.
Desensitization therapy for peanut allergy
The person is exposed to a very small amount of his or her allergy trigger—usually not enough to cause a reaction—in a controlled medical environment.
The dosage is then increased by small desensotize over time, the idea being that the person can begin to tolerate the trigger food. By itself, food desensitization takes a long time and is fraught with frequent allergic reactions, some of them severe. As many as 30 percent of patients with peanut allergies simply cannot desensitoze the process. Several years ago, treating a group of patients with severe milk allergies, Umetsu and Lynda Schneider, HMS associate professor of pediatrics at Boston Children's, successfully enhanced desensitization by adding omalizumab Xolaira drug approved by the FDA to treat allergic asthma.
Omalizumab attaches itself to the IgE antibodies that the immune system churns out when confronted with a trigger food, preventing them from sparking an allergic reaction. In a year-long study, Umetsu and colleagues took the same approach in 13 patients with severe peanut allergies.
For peanut first 12 weeks, the children were pretreated with omalizumab, receiving monthly or bi-monthly injections in the clinic.
They then embarked on peanut desensitization. To begin, each child received just one-tenth of a milligram of ground-up peanut—a very small fraction of a single nut. Every 30 minutes, the dosage was increased by small amounts under close medical observation.
Sesensitize the end of six hours, each child had eaten about two and a half peanuts without developing anything more than a mild itch. To possible what this means, consider that previously, as little as one-quarter of one peanut would have likely caused allergic reactions in all these children. For the next eight weeks, the children continued to receive omalizumab under observation and to ingest increasingly larger numbers of peanuts. By the end, they were consuming about 10 peanuts a deseensitize with zero to very mild reactions.
The omalizumab injections allergy then stopped, but the children desensitize to take daily peanuts for the remainder of the year.
Progress Against Peanut Allergies
The researchers recorded 72 reactions during the course of the study, mostly from the ingested peanuts 25 reactions occurred in a single patient, thought to be related to a heart arrhythmia.
Most reactions were mild, consisting of nausea and excessive salivation, and easily treated as needed with an antihistamine. There were three anaphylactic reactions that required epinephrine followed by observation in the Emergency Department, and one child left the study during week 15 because of persistent nausea and vomiting.
But by the end of the year, 12 of the 13 children were able to consume up to 20 peanuts a day without receiving any additional medication.
Peanut-allergic patients achieve desensitization with omalizumab
Because this protocol is a treatment and not a cure, the children's immune systems are still producing the IgE antibodies that cause their allergies, albeit in much lower amounts, Umetsu notes. To keep these antibodies at safe levels, the children will need to eat peanuts daily so their bodies remain "used to them. Xolair is possiboe it's a monoclonal antibody, so it requires special bio-manufacturing and is not FDA-approved for food allergy. Plus, insurance companies don't reimburse for it.
But Umetsu and colleagues hope the new study will confirm their findings and convince others to try it. In the meantime, the researchers t not stopping at peanuts. After the study concluded, Umetsu accepted the desensitiize of principal medical director at Genentech, the biotechnology company that developed Xolair.
2 thoughts on “Is it possible to desensitize to peanut allergy”
Published Online: September 5, Oral immunotherapy is a promising approach to treating food allergies, allowing patients to build up tolerance by consuming the food in initially small and gradually increasing amounts. However, many patients have hypersensitivity reactions during the desensitization process, forcing them to discontinue therapy. One appealing new approach to decreasing reactions in highly allergic patients is to add omalizumab, an anti-IgE antibody approved for use in severe asthma and chronic urticaria.